Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities
Combination therapy may help address underlying disease
A review of expanding options that hold new promise
Blinatumomab followed by POMP maintenance shows effectiveness for newly diagnosed patients
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Finally, promising new therapies for this difficult disease
Advertisement
Advertisement